WallStreetZenWallStreetZen

NASDAQ: CLNN
Clene Inc Stock

$4.80+0.01 (+0.21%)
Updated Jul 18, 2024
CLNN Price
$4.80
Fair Value Price
-$0.51
Market Cap
$30.82M
52 Week Low
$4.59
52 Week High
$16.36
P/E
-0.52x
P/B
7.23x
P/S
88.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$620.00k
Earnings
-$48.81M
Gross Margin
78.7%
Operating Margin
-7,109.35%
Profit Margin
-7,873.2%
Debt to Equity
9.57
Operating Cash Flow
-$28M
Beta
0.31
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CLNN Overview

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLNN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CLNN ($4.80) is overvalued by 1,041.29% relative to our estimate of its Fair Value price of -$0.51 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CLNN ($4.80) is not significantly undervalued (1,041.29%) relative to our estimate of its Fair Value price of -$0.51 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CLNN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLNN due diligence checks available for Premium users.

Be the first to know about important CLNN news, forecast changes, insider trades & much more!

CLNN News

Valuation

CLNN fair value

Fair Value of CLNN stock based on Discounted Cash Flow (DCF)
Price
$4.80
Fair Value
-$0.51
Undervalued by
1,034.83%
CLNN ($4.80) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLNN ($4.80) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLNN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CLNN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.52x
Industry
-26.99x
Market
29.86x

CLNN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.23x
Industry
6.19x
CLNN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CLNN's financial health

Profit margin

Revenue
$73.0k
Net Income
-$11.1M
Profit Margin
-15,178.1%
CLNN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLNN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$45.1M
Liabilities
$40.8M
Debt to equity
9.57
CLNN's short-term assets ($32.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLNN's short-term assets ($32.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLNN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CLNN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.1M
Investing
$71.0k
Financing
-$19.0k
CLNN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CLNN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CLNN$30.82M+0.21%-0.52x7.23x
VYNE$31.24M-4.44%-1.78x0.37x
RVPH$30.15M-9.62%-0.68x-22.40x
EVGN$30.12M-3.72%-1.29x3.63x
PLUR$29.91M-3.14%-1.34x-84.01x

Clene Stock FAQ

What is Clene's quote symbol?

(NASDAQ: CLNN) Clene trades on the NASDAQ under the ticker symbol CLNN. Clene stock quotes can also be displayed as NASDAQ: CLNN.

If you're new to stock investing, here's how to buy Clene stock.

What is the 52 week high and low for Clene (NASDAQ: CLNN)?

(NASDAQ: CLNN) Clene's 52-week high was $16.36, and its 52-week low was $4.59. It is currently -70.66% from its 52-week high and 4.58% from its 52-week low.

How much is Clene stock worth today?

(NASDAQ: CLNN) Clene currently has 6,421,686 outstanding shares. With Clene stock trading at $4.80 per share, the total value of Clene stock (market capitalization) is $30.82M.

Clene stock was originally listed at a price of $202.60 in Aug 2, 2018. If you had invested in Clene stock at $202.60, your return over the last 5 years would have been -97.63%, for an annualized return of -52.69% (not including any dividends or dividend reinvestments).

How much is Clene's stock price per share?

(NASDAQ: CLNN) Clene stock price per share is $4.80 today (as of Jul 18, 2024).

What is Clene's Market Cap?

(NASDAQ: CLNN) Clene's market cap is $30.82M, as of Jul 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Clene's market cap is calculated by multiplying CLNN's current stock price of $4.80 by CLNN's total outstanding shares of 6,421,686.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.